ChoA Pharmaceutical Co., LTD. (KOSDAQ:034940)
2,725.00
-20.00 (-0.73%)
At close: Sep 11, 2026
KOSDAQ:034940 Revenue
ChoA Pharmaceutical Co., LTD. had revenue of 15.18B KRW in the quarter ending June 30, 2026, with 11.31% growth. This brings the company's revenue in the last twelve months to 61.16B, up 1.50% year-over-year. In the year 2025, ChoA Pharmaceutical Co., LTD. had annual revenue of 59.31B, down -5.40%.
Revenue (ttm)
61.16B
Revenue Growth
+1.50%
P/S Ratio
0.28
Revenue / Employee
227.37M
Employees
269
Market Cap
16.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.31B | -3.38B | -5.40% |
| Dec 31, 2024 | 62.69B | -280.00M | -0.44% |
| Dec 31, 2023 | 62.97B | -5.91B | -8.57% |
| Dec 31, 2022 | 68.88B | 11.32B | 19.66% |
| Dec 31, 2021 | 57.56B | -7.80B | -11.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 94.89B |
| WooGene B&G | 56.49B |
| CXI Healthcare Technology Group | 51.45B |
| Seoul Pharma | 51.08B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |
| BIFIDO | 14.63B |